28 completed, 8 terminated, 2 active not recruiting, 1 not yet recruiting. 29 Phase 2, 14 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 21, Terminated 5, Active not recruiting 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 14 | Completed 8, Terminated 5, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Waldenstrom's Macroglobulinemia: new trials by email Literature Review of Waldenstrom's Macroglobulinemia trials Research Report on Waldenstrom's Macroglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Mavorixafor, Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 1 | Completed | X4 Pharmaceuticals | 16 | 2020-04-30 | 2024-08-27 |
| A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia Ulocuplumab, Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 1 | Terminated | Dana-Farber Cancer Institute | 13 | 2017-10-20 | 2024-05-03 |
| Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia CT-1530 - Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | Centaurus Biopharma Co., Ltd. | 200 | 2017-04-01 | 2017-07-19 |
| Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 31 | 2016-01-01 | 2022-12-07 |
| Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia GS-1101 - Waldenstrom's Macroglobulinemia | Phase 2 | Terminated | Dana-Farber Cancer Institute | 5 | 2015-10-01 | 2017-01-11 |
| Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Fluzone High Dose Vaccine, Standard of care/Placebo - Influenza, Multiple Myeloma | Phase 2 | Completed | Yale University | 122 | 2015-09-01 | 2019-01-30 |
| Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Ixazomib, Dexamethasone, Rituximab - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 26 | 2015-04-01 | 2020-09-02 |
| Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly - Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 5 | 2014-11-01 | 2018-01-09 |
| Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's Bortezomib-Rituximab-Bendamustine - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Fondazione Italiana Linfomi - ETS | 38 | 2014-06-01 | 2020-12-02 |
| Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia IMO-8400 - Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | Terminated | Idera Pharmaceuticals, Inc. | 31 | 2014-03-01 | 2019-09-10 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Ublituximab, Lenalidomide - Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | TG Therapeutics, Inc. | 10 | 2012-11-21 | 2022-05-11 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Ublituximab - Non-Hodgkins Lymphoma, B-cell Lymphoma | Phase 1 / Phase 2 | Completed | TG Therapeutics, Inc. | 39 | 2012-07-19 | 2022-11-21 |
| Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia PCI-32765 - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 63 | 2012-05-01 | 2020-01-21 |
| Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Dexamethasone, Carfilzomib, Rituximab - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 31 | 2011-10-01 | 2018-11-20 |
| Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia pomalidomide, dexamethasone, rituximab - Waldenstrom's Macroglobulinemia | Phase 1 | Terminated | Steven P. Treon, MD, PhD | 7 | 2010-05-01 | 2016-07-25 |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Everolimus, Rituximab, Bortezomib - Waldenstrom's Macroglobulinemia | Phase 1 / Phase 2 | Terminated | Dana-Farber Cancer Institute | 46 | 2010-04-01 | 2021-04-23 |
| Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders Multiple Myeloma, Waldenstrom's Macroglobulinemia | Active not recruiting | Dana-Farber Cancer Institute | 656 | 2009-12-30 | 2026-05-05 | |
| Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia RAD001 - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 33 | 2009-11-01 | 2018-10-03 |
| LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia LBH589 - Waldenstrom's Macroglobulinemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 39 | 2009-07-01 | 2021-01-28 |
Showing 20 of 40. Sign in to see all of them.
Waldenstrom Macroglobulinemia (40) · Multiple Myeloma (9) · Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Non-Hodgkin (6) · Recurrence (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, B-Cell (4) · Hodgkin Disease (3) · Immunoblastic Lymphadenopathy (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Anaplastic (2) · Myelodysplastic Syndromes (2) · Neoplasms, Plasma Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)
Blood Protein Disorders (40) · Cardiovascular Diseases (40) · Hematologic Diseases (40) · Hemic and Lymphatic Diseases (40) · Hemorrhagic Disorders (40) · Hemostatic Disorders (40) · Immune System Diseases (40) · Immunoproliferative Disorders (40) · Lymphatic Diseases (40) · Lymphoproliferative Disorders (40) · Neoplasms (40) · Neoplasms by Histologic Type (40) · Paraproteinemias (40) · Vascular Diseases (40) · Neoplasms, Plasma Cell (38)
Rituximab (11) · Bortezomib (6) · Dexamethasone (6) · Calcium Dobesilate (4) · ibrutinib (4) · Everolimus (2) · Lenalidomide (2) · bazlitoran (2) · carfilzomib (2) · ublituximab (2) · 10-propargyl-10-deazaaminopterin (1) · AVN 944 (1) · Alemtuzumab (1) · Antibodies, Monoclonal (1) · Commerce (1)
Dana-Farber Cancer Institute (19) · Idera Pharmaceuticals, Inc. (2) · Millennium Pharmaceuticals, Inc. (2) · Steven P. Treon, MD, PhD (2) · TG Therapeutics, Inc. (2) · Acrotech Biopharma Inc. (1) · Amgen (1) · Centaurus Biopharma Co., Ltd. (1) · Eli Lilly and Company (1) · Fondazione Italiana Linfomi - ETS (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · Meletios A. Dimopoulos (1) · SWOG Cancer Research Network (1) · University of Michigan Rogel Cancer Center (1)
United States (36) · Greece (2) · China (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1)
Irene Ghobrial, MD (5) · Steven P. Treon, MD, MA, PhD (4) · Steven Treon, MD, MA, PhD (3) · Jorge J. Castillo, MD (2) · Mark Cornfeld, MD, MPH (2) · Steven P Treon, MD, PhD (2) · Andrew Branagan, MD (1) · Andrew Branagan, MD, PhD (1) · Giulia Benevolo, MD (1) · John E. Levine, MS MD (1) · Joshua Espstein, DSC (1) · Lorella Orsucci, MD (1)
PMID 40674744, PMID 18713945, PMID 19118065, PMID 19506160, PMID 20142586, PMID 21566092, PMID 23287861, PMID 24352795, PMID 24859363, PMID 25853747, PMID 26139427, PMID 27836860, PMID 29661775, PMID 30044692, PMID 32822482, PMID 32931398, PMID 33683337, PMID 34289017, PMID 34398557, PMID 34531537, PMID 41671559
2019 (1), R01FD003743 (1), U10CA032102 (1)